Moderna plans to issue $1.25 billion in fresh equity following 20% stock jump

US News

Moderna in Cambridge, MA is pictured on Feb. 28, 2020.

David L. Ryan | The Boston Globe via Getty Images

Biotech company Moderna, which is testing one of the leading coronavirus vaccine candidates, plans to issue at least $1.25 billion in fresh stock after releasing the results of its phase 1 trial, the company said Monday.  

The announcement comes after Moderna reported positive data on its early-stage human trial for a Covid-19 vaccine earlier Monday. The closely watched vaccine trial produced Covid-19 antibodies in all 45 participants, sending the company’s shares surging nearly 20%. 

Moderna said it expects to primarily use the proceeds to fund the manufacturing and distribution of its vaccine candidate, mRNA-1273 once it’s approved by federal regulators. Morgan Stanley is the running the deal. Moderna is giving the underwriters a 30-day option to buy up to an additional $187.5 million in common stock. 

If there are any remaining proceeds, the company hopes “to fund clinical development and drug discovery in existing and new therapeutic areas; to fund further development of its mRNA technology platform and the creation of new modalities; or to fund working capital and other general corporate purposes.” 

Products You May Like

Articles You May Like

 India’s PSLV rocket launches nine satellites in final mission of 2022
Carol Malone Book Signing to Movie Deal.
Black Friday online sales to hit new record, expected to top $9 billion
Michigan man arrested in threats to FBI Director Chris Wray, Rep. Garamendi
Klarna CEO says firm was ‘lucky’ to cut jobs when it did, targets profitability in 2023

Leave a Reply

Your email address will not be published.